Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-101 AcuStream microdose study in presbyopia
ACTRN12619001325190Phase 2Not yet recruiting
- Sponsor
- Kedalion Therapeutics
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KT101 in presbyopia (4 arms), sponsored by Kedalion Therapeutics. Primary endpoint: Change from baseline distance-corrected near visual acuity. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
KT101
03
Conditions
presbyopia
Beyond the preview
Go deeper on ACTRN12619001325190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001325190.